CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 277 filers reported holding CLOVIS ONCOLOGY INC in Q2 2017. The put-call ratio across all filers is 0.51 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $1,307,000 | +14.4% | 332,635 | +333.2% | 1.76% | +30.4% |
| Q2 2019 | $1,142,000 | -52.5% | 76,782 | -20.7% | 1.35% | -59.4% |
| Q1 2019 | $2,403,000 | +25.8% | 96,820 | -9.0% | 3.34% | +29.3% |
| Q4 2018 | $1,910,000 | -37.5% | 106,342 | +2.1% | 2.58% | -9.9% |
| Q3 2018 | $3,058,000 | -4.6% | 104,116 | +47.7% | 2.86% | -2.6% |
| Q2 2018 | $3,206,000 | +66.2% | 70,498 | +93.0% | 2.94% | +45.4% |
| Q1 2018 | $1,929,000 | +45.4% | 36,529 | +87.2% | 2.02% | +49.0% |
| Q4 2017 | $1,327,000 | -7.9% | 19,517 | +11.6% | 1.36% | -23.1% |
| Q3 2017 | $1,441,000 | +36.6% | 17,493 | +55.3% | 1.76% | +10.5% |
| Q2 2017 | $1,055,000 | +274.1% | 11,264 | -23.2% | 1.60% | +195.2% |
| Q1 2016 | $282,000 | – | 14,666 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |